Galena Biopharma, Inc.
310 North State Street
Suite 208
Lake Oswego,
OR 97034
United States - Map
Phone: 855-855-4253
Website: http://www.galenabiopharma.com
| Index Membership: | N/A | | Sector: | Healthcare | | Industry: | Biotechnology | | Full Time Employees: | 12 |
|
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing oncology treatments to address major unmet medical needs to advance cancer care. It is developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide. The companys lead product candidate includes NeuVax (nelipepimut-S or E75), which is in Phase 3 clinical trials for preventing the recurrence of breast cancer. It also develops Folate Binding Protein-E39, a targeted vaccine that is in Phase 1/2 clinical trials for the prevention of recurrence in gynecological cancers, such as ovarian and endometrial adenocarconimas. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in Lake Oswego, Oregon. Key Statistics
| |
| | Pay | Exercised | Dr. Mark J. Ahn Ph.D.,
50
Chief Exec. Officer, Pres, Director and Member of Strategy Committee | 665.00k | 0.00 | Dr. Mark W. Schwartz Ph.D.,
58
Chief Operating Officer and Exec. VP | 455.00k | 0.00 | Dr. Rosemary Mazanet M.D., Ph.D.,
57
Chief Medical Officer and Exec. VP | 460.00k | 0.00 | Mr. Ryan M. Dunlap ,
43
Principal Financial Officer, Principal Accounting Officer, Director of Fin., Controller and Director | N/A | N/A | Dr. Hana B. Moran Ph.D.,
VP of Regulatory Affairs and Compliance | N/A | N/A |
|
| | Amounts are as of 2012-12-30 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.01(0.20%) 11:46AM EDT - Nasdaq Real Time Price